DeCure for Maturity-onset diabetes of the young type 2
DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for maturity-onset diabetes of the young type 2 — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMaturity-onset diabetes of the young type 2 maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for maturity-onset diabetes of the young type 2 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
glucokinase (GCK) — GCK is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4DCH · 1.79 Å · ligand (2R)-3-cyclopentyl-2-[4-(methylsulfonyl)phenyl]-N-(1,3-thiazol-2-yl)propanamide (4DC). Experimental structure, not a prediction.
What the evidence adds up to
Maturity-onset diabetes of the young type 2 is not mentioned in any of the three abstracts. The abstracts discuss youth-onset type 2 diabetes, defined as type 2 diabetes diagnosed before age 40, and specifically paediatric type 2 diabetes in children aged 10–18 years. One consensus report from 2016 states that type 2 diabetes in children is different from both type 1 diabetes and type 2 diabetes in adults, and that clear strategies for research, prevention, and treatment in these patients are needed. The report does not provide any numerical data on survival, response rates, or sample sizes.
A 2021 retrospective cohort study of 829 commercially insured patients aged 10–18 years with incident type 2 diabetes initially treated with metformin alone found that within a median follow-up of 2.9 years, one-quarter (207 patients) underwent treatment escalation: 88 to insulin and 164 to a non-insulin antihyperglycaemic agent. Younger patients were more likely to receive insulin before other drugs. Age at diagnosis (hazard ratio 1.14, 95% CI 1.07–1.21), medication adherence (HR 4.10, 95% CI 2.96–5.67), Hispanic ethnicity (HR 1.83, 95% CI 1.28–2.61), and diabetes-related complications (HR 1.78, 95% CI 1.15–2.74) were positively associated with treatment escalation. The authors note that off-label use of non-insulin antihyperglycaemics occurred, most commonly among older adolescents.
A 2024 scoping review characterises young-onset type 2 diabetes as having more aggressive pathology than later-onset disease, leading to earlier macrovascular and microvascular complications. The review does not report specific complication rates, sample sizes, or treatment outcomes. It calls for early detection, comprehensive risk assessment, and multifaceted glycemic management to improve quality of life and life expectancy.
What is still missing: no randomised controlled trials comparing specific drug regimens in maturity-onset diabetes of the young type 2 are cited; the available data come from retrospective claims analysis and narrative reviews. There is no evidence on which non-insulin antihyperglycaemic agents, if any, are effective for this specific monogenic subtype. Funding for prospective trials stratified by genetic diagnosis, and trial designs that separate MODY2 from other forms of youth-onset diabetes, are lacking.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Diabetes Care · 2016 · 389 citations · open access
Youth-Onset Type 2 Diabetes Consensus Report: Current Status, Challenges, and Priorities
AbstractType 2 diabetes is a significant and increasing burden in adolescents and young adults. Clear strategies for research, prevention, and treatment of the disease in these vulnerable patients are needed. Evidence suggests that type 2 diabetes in children is different not only from type 1 but also from type 2 diabetes in adults. Understanding the unique pathophysiology of type 2 diabetes in youth, as well as the risk of complications and the psychosocial impact, will enable industry, academia, funding agencies, advocacy groups, and regulators to collectively evaluate both current and future research, treatment, and prevention approaches. This Consensus Report characterizes type 2 diabetes in children, evaluates the fundamental differences between childhood and adult disease, describes the current therapeutic options, and discusses challenges to and approaches for developing new treatments.
Pediatric Diabetes · 2021 · 12 citations · open access
<scp>Real‐world</scp> treatment escalation from metformin monotherapy in <scp>youth‐onset</scp> Type 2 diabetes mellitus: A retrospective cohort study
AbstractBACKGROUND: Due to high rates of comorbidities and rapid progression, youth with Type 2 diabetes may benefit from early and aggressive treatment. However, until 2019, the only approved medications for this population were metformin and insulin. OBJECTIVE: To investigate patterns and predictors of treatment escalation within 5 years of metformin monotherapy initiation for youth with Type 2 diabetes in clinical practice. SUBJECTS: Commercially-insured patients with incident youth-onset (10-18 years) Type 2 diabetes initially treated with metformin only. METHODS: Retrospective cohort study using a patient-level medical claims database with data from 2000 to 2020. Frequency and order of treatment escalation to insulin and non-insulin antihyperglycemics were determined and categorized by age at diagnosis. Cox proportional hazards regression was used to evaluate potential predictors of treatment escalation, including age, sex, race/ethnicity, comorbidities, complications, and metformin adherence (medication possession ratio ≥ 0.8). RESULTS: The cohort included 829 (66% female; median age at diagnosis 15 years; 19% Hispanic, 17% Black) patients, with median 2.9 year follow-up after metformin initiation. One-quarter underwent treatment escalation (n = 207; 88 to insulin, 164 to non-insulin antihyperglycemic). Younger patients were more likely to have insulin prescribed prior to other antihyperglycemics. Age at diagnosis (HR 1.14, 95% CI 1.07-1.21), medication adherence (HR 4.10, 95% CI 2.96-5.67), Hispanic ethnicity (HR 1.83, 95% CI 1.28-2.61), and diabetes-related complications (HR 1.78, 95% CI 1.15-2.74) were positively associated with treatment escalation. CONCLUSIONS: In clinical practice, treatment escalation for pediatric Type 2 diabetes differs with age. Off-label use of non-insulin antihyperglycemics occurs, most commonly among older adolescents.
Clinical Diabetes · 2024 · 1 citations · open access
Profiling of Macrovascular and Microvascular Complications in Young-Onset Type 2 Diabetes: A Scoping Review
AbstractYoung-onset type 2 diabetes is defined as type 2 diabetes diagnosed before the age of 40 years. It is characterized by more aggressive pathology compared with type 2 diabetes diagnosed later in life, leading to earlier susceptibility to macrovascular and microvascular complications. This scoping review comprehensively profiles the complications associated with young-onset type 2 diabetes. Early detection of these complications, comprehensive risk assessment, and multifaceted glycemic management will improve quality of life and overall life expectancy in this population.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
